Clinical trial
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
NCT00040404 · Cephalon, Industry · Terminated
Key facts
| NCT number | NCT00040404 |
|---|---|
| Title | Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease |
| Lead sponsor | Cephalon, Industry |
| Collaborators | H. Lundbeck A/S Industry The Parkinson Study Group |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug, Other |
| Interventions | CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg, Placebo Comparator |
| Enrollment | 806 |
| Start date | Mar 1, 2002 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Jun 27, 2002 |
| Last update posted | May 10, 2012 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: